2024 was a challenging year for M&A activity in the medical technology (“MedTech”) industry. Although some sectors experienced a rebound in deal volume, MedTech dealmakers were disproportionately affected by a difficult regulatory environment, elevated interest rates, and deflated valuations.
Strategic buyers, private equity sponsors, and other MedTech participants entered 2025 with cautious optimism, encouraged by the potential for a pro-growth agenda and a deregulatory backdrop under a new presidential administration. Industry stakeholders hoped for renewed M&A momentum, particularly in sectors aligned with healthcare innovation and digital transformation.
While this broader resurgence has yet to materialize across the M&A landscape, MedTech deal activity has begun to show meaningful momentum in 2025, as dealmakers seek to capitalize on innovations in artificial intelligence (AI), digital health platforms, and advanced surgical technologies.
1. Fewer Transactions, Larger Dollar Amounts
Although MedTech M&A activity decreased slightly from Q4 2024 (62 transactions, per J.P. Morgan) to Q1 2025 (57 transactions), the upfront value of these deals increased dramatically (from $2.7 billion to $9.2 billion). This uptick reflects both large-cap deals (such as the Stryker (NYSE: SYK) $4.9 billion acquisition of Inari Medical (NASDAQ: NARI) and the Zimmer Biomet (NYSE: ZBH) $1.2 billion acquisition of Paragon 28 (NYSE: FNA)) and broader valuation trends: median upfront payments rose from $14 million in Q4 2024 to $250 million in Q1 2025.
These figures suggest that M&A participants are placing greater emphasis on high-value investments and acquisitions of more mature companies with deeper product pipelines or commercial traction. Additionally, buyers appear more willing to pursue singular strategic deals that align with core growth priorities rather than broad-based asset aggregation.
This trend appears poised to continue throughout 2025. For example, Thermo Fisher Scientific recently announced that it will acquire Solventum’s purification and filtration business for $4.1 billion, with the deal expected to close by year-end.
2. Innovations in Surgical Solutions and AI Are Driving Deal Flow
The rapid evolution of MedTech technologies—particularly those offering advanced surgical solutions, specialized capabilities, and real-world data analytics capabilities—has been a major driver of deal activity in 2025. Buyers are increasingly targeting companies with differentiated procedural capabilities that can be integrated into broader care platforms.
One notable example is Stryker’s $4.9 billion acquisition of Inari Medical, which expanded Stryker’s presence in the cardiovascular and peripheral vascular markets. Inari’s proprietary thrombectomy devices generate real-time procedural and outcomes data, aligning with Stryker’s strategy of integrating procedural intelligence, clinical analytics, and AI-assisted technologies into its surgical platforms. The transaction builds on Stryker’s recent AI-focused acquisitions, including its 2024 purchase of care.ai.
Other high-profile surgical technology deals in H1 2025 include: the Boston Scientific (NYSE: BSX) $900 million acquisition of Bolt Medical, Boston Scientific’s $540 million acquisition of SoniVie, Zydus Lifesciences’ $281 million acquisition of Amplitude Surgical, and Argon Medical’s purchase of SeQure and DraKon. These deals reflect a focus on expanding portfolios in niche, high-growth specialties such as renal denervation, peripheral vascular intervention, and orthopedic reconstruction.
In parallel, digital health and AI-driven solutions have drawn increasing attention. Key transactions include: the Illumina (NASDAQ: ILMN) acquisition of SomaLogic from Standard BioTools (NASDAQ: LAB) (strengthening Illumina’s multi-omics and proteomics capabilities through algorithmic analysis), MoveUp’s acquisition of Deep Structure AI (adding advanced deep learning capabilities to MoveUp’s digital health platform), and SyntheticMR’s acquisition of Combinostics Oy (expanding its portfolio of AI-based diagnostics tools). Interest in companies with embedded, FDA-cleared AI functionality (especially those operating within regulated clinical workflows) will remain a key driver of MedTech M&A through the second half of 2025.
These deals illustrate the growing importance of machine learning, patient-specific modeling, and predictive analytics in the future of MedTech. As reimbursement models increasingly emphasize outcomes, solutions that incorporate real-world data will be central to product differentiation.
3. Portfolio Optimization and Specialty Consolidation Remain Priorities
Large-cap MedTech companies continue to restructure and realign their portfolios through strategic acquisitions and divestitures targeting high-growth, high-margin therapeutic areas. Companies are actively divesting non-core segments and reinvesting proceeds into platforms with long-term market leadership potential.
For example, Zimmer’s acquisition of Paragon 28, a leader in foot and ankle implants, vertically enhanced Zimmer’s specialty surgical platform while addressing growing demographic demand for aging-related procedures. Similarly, Becton Dickinson (NYSE: BDX) recently announced its intent to separate its Biosciences & Diagnostic Solutions business into a standalone company. This move underscores BDX’s focus on streamlined operations and more concentrated R&D investment, while also reflecting a broader industry shift toward capital discipline and strategic prioritization.
Looking Ahead
While analysts anticipate continued demand for AI-driven technologies—particularly those generating real-world data and clinical insights—broader macroeconomic factors may temper deal appetite in the near term. Risks such as tariff escalation, valuation volatility, and regulatory uncertainty remain as material headwinds. Persistent concerns around inflation, geopolitical tensions, and policy shifts may lead to prolonged deal timelines or heightened buyer caution.
Nonetheless, the early trends in 2025 suggest that innovation-led dealmaking and focused capital deployment will continue to define the MedTech M&A landscape. Well-capitalized strategic buyers and sponsors with a clear digital health thesis are likely to continue pursuing targeted acquisitions that enhance long-term capabilities. As a result, dealmakers should remain focused on identifying assets with defensible intellectual property, scalable infrastructure, and regulatory clarity.
[View source.]
